[Effects of Ucf-101 on expression of Omi/HtrA2 in kidneys of postasphyxial neonatal rats].
OBJECTIVE
To investigate the expression of serine protease Omi/HtrA2 in kidneys of postasphyxial neonatal rats, and to study the effects of Ucf-101 on apoptosis and the expression of Omi/HtrA2 in these rats.


METHODS
Seventy-two neonatal Wistar rats of 7-10 days old were randomly divided into 3 groups: control, postasphyxial model, Ucf-101-treated postasphyxialThe postasphyxial model was established by normobaric asphyxiaExpression of Omi/HtrA2 was determined with streptavidin-peroxidase immunohistochemistry 2, 24 and 48 hrs after asphyxia. Terminal deoxynuleotidyl-mediated nick end labeling (TUNEL) was used to ascertain the apoptosis of renal cells.


RESULTS
Compared with the control group, OmiHtrA2 expression in renal cells began to increase 2 hrs after asphyxia and peaked at 24 hrs. The expression of Omi/HtrA2 in the Ucf-101-treated postasphyxial group was significantly lower than that in the postasphyxial model group (P<0.01). TUNEL-positive cells began to increase 2 hrs after asphyxia and peaked at 24 hrs in the postasphyxial model group when compared with the control group. The number of TUNEL-positive cells in the Ucf-101-treated postasphyxial group was significantly lower than that in the postasphyxial model group at all time points (P<0.01).


CONCLUSIONS
The expression of Omi/HtrA2 in kidneys is increased in postasphyxial neonatal rats. The increased Omi/HtrA2 expression may play an important role in the development of postasphyxial renal injury. Treatment with Ucf-101 can reduce the expression of Omi/HtrA2 in kidneys of postasphyxial neonatal rats and thus reduce renal tububar epithelial cell apoptosis.
Hua
Bing
B
Department of Neonatology, Affiliated Hospital, Luzhou Medical College, Luzhou, Sichuan 646000, China.
Dong
Wen-Bin
WB
Li
Qing-Ping
QP
Feng
Zhi-Qiang
ZQ
Yu
Hong
H
Zhai
Xue-Song
XS
Lei
Xiao-Ping
XP
D000818:Animals; D000831:Animals, Newborn; D017209:Apoptosis / Q000187:drug effects; D001238:Asphyxia Neonatorum / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D005260:Female; D000074923:High-Temperature Requirement A Serine Peptidase 2; D006801:Humans; D007150:Immunohistochemistry; D020287:In Situ Nick-End Labeling; D007231:Infant, Newborn; D007668:Kidney / Q000737:chemistry*; D008297:Male; D024101:Mitochondrial Proteins / Q000032:analysis / Q000037:antagonists & inhibitors*; D011744:Pyrimidinones / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D012697:Serine Endopeptidases / Q000032:analysis; D013871:Thiones / Q000494:pharmacology / Q000627:therapeutic use*
D024101:Mitochondrial Proteins; D011744:Pyrimidinones; D013871:Thiones; C501517:UCF 101; D012697:Serine Endopeptidases; C000615914:HTRA2 protein, human; D000074923:High-Temperature Requirement A Serine Peptidase 2